Volume 6 Issue 1 January 2022 ISSN:5101195-3

KOSOVA JOURNAL OF SURGERY

PAPERS PRESENTED AT THE FIRST CLINICAL CONGRESS OF THE KOSOVA COLLEGE OF SURGEONS SEPTEMBER 24-26, 2021





BELLAL JOSEPH: Breaking the Frailty Code: Emergency General Surgery in the Elderly

DEMETRIUS LITWIN: Hand-Assisted Laparoscopic Living Donor Hepatectomy

LIOR LEVY, ABASS SMILEY, RIFAT LATIFI: Independent Predictors of In-Hospital Mortality in Patients Undergoing Emergency Admission for Arterial Embolism and Thrombosis in the USA: A 10-Year National Dataset

LIOR LEVY, ABBAS SMILEY, RIFAT LATIFI: Mortality in Emergently Admitted Patients with Empyema: An Analysis of 18,033 Patients





Independent Predictors of In-Hospital Mortality in Patients Undergoing Emergency Admission for Arterial Embolism and Thrombosis in the USA: A 10-Year National Dataset

Lior Levy, BA,1 Abbas Smiley, MD, MSc, PhD,2 Rifat Latifi, MD, FACS, FKCS, FICS,*3

- 1. Medical Student, New York Medical College, Valhalla, NY.
- 2. Assistant Professor, Department of Surgery, Westchester Medical Center Health and New York Medical College, School of Medicine, Valhalla, New York
- 3. Department of Surgery, Westchester Medical Center Health, Valhalla, NY 10595, USA.

*The Corresponding author:

RIFAT LATIFI, MD, FACS, FICS, FKCS

Minister of Health of Kosova, Department of Surgery, Westchester Medical Center Health, Taylor Pavilion, Suite D334, 100 Woods Road, Valhalla, NY 10595, USA.

e-mail: Rifat.Latifi@wmchealth.org

Funding: None. Disclosure: None

Abstract

Background: Arterial embolism and thrombosis were estimated to account for 25% of deaths globally in 2010 and are the leading cause of mortality. As a global shift of morbidity and mortality from infectious diseases to non-infectious causes, cardiovascular diseases became the leading cause of death.

Objective: The goal of this study was to evaluate independent predictors of in-hospital mortality in non-elderly adult and elderly patients undergoing emergency admission for complicated arterial embolism and thrombosis.

Methods: Demographic and clinical data were obtained from the National Inpatient Sample (NIS), 2005-2014, to evaluate non-elderly adult patients (age 18-64 years) and elderly patients (65+ years) with arterial embolism and thrombosis who underwent emergency admission. Multivariable logistic regression models were used to identify association of predictors and in-hospital mortality.

Results: A total of 1,041 non-elderly adult patients and 1,260 elderly patients were included in the study, of which 40.1% and 49.0% were females, respectively. Their mean (SD) age was 55 (7) years and 75 (7) years, respectively. Overall mortality was 0.9% in the adult patients and 2.0% in the elderly patients, of which 44.4% and 68.0% were females, respectively. Backward multivariable lo-

gistic regression analysis demonstrated risk factors of mortality in operated patients: delayed operation and frailty index for adults, and female sex and frailty index for elderly.

Conclusion: In operated patients, the main risk factors of mortality were delayed operation and frailty index for adults, and female sex and frailty index for elderly.

Key Words: Arterial embolism and thrombosis, in-hospital mortality, hospital length of stay.

Introduction

Thromboembolism is a term referring to large clots that dislodge from the surface of atherosclerotic lesions and occlude distal arteries causing immediate ischemia. Atrial thrombosis, the obstruction of blood flow due to the formation of clot, may result in tissue anoxia and damage. Arterial embolism results when a mass of tissue or a foreign substance travel through the vascular tree, to eventually lodge in a distal artery where it blocks blood flow. This obstruction results in ischemia, organ dysfunction and potential infarction. The most common manifestations are strokes and acute lower limb ischemia. Complications of arterial embolism and thrombosis are a chief cause of dysfunction and death in the United States. Global Burden of Diseases 2010 clearly documents the major impact of arterial thrombosis on global disease burden

because it is the pathological mechanism underlying most cases of ischemic heart disease and ischemic stroke. Early diagnosis and timely surgical intervention are the cornerstones of modern treatment and are essential to reduce the high mortality associated with this entity. However, surgical and intensive care patients are at an enhanced risk for arterial embolization due to pre-existing conditions such as hypertension, cardiovascular abnormalities, electrolyte disorders and atherosclerotic disease. Unlike myocardial infarction and stroke associated mortality, insufficient research has focused on optimizing care management of patients with arterial emboli and thrombosis to reduce morbidity and mortality. Signs of the shifting outlook for acute pulmonary embolism care can be seen in the expeditious promulgation of the pulmonary embolism response team (PERT) concept and the adoption of novel strategies to treat acute pulmonary embolism with endovascular technologies. Risk factors for adverse outcomes following emergency surgery for arterial emboli and thrombosis complications are still debated. Some factors were repeatedly found to be the predictors of mortality including but not limited to emergency surgery, age, and patient health status. Nonetheless, the prognostic value of emergency surgery status was challenged with regards to arterial emboli and thrombosis surgical outcome. The aim of this study was to evaluate the predictors of in-hospital mortality following emergency admission for arterial emboli and thrombosis to help identify ways to improve the field and achieve better patient outcomes.

Methods

The Healthcare Cost and Utilization Project (HCUP) was established to provide multistate, administrative, population-based data on patients in a uniform format. The data are designed for health services research to enhance health care provision. The National Inpatient Sample (NIS), a large administrative database produced by the Agency for Healthcare Research and Quality (AHRQ), has been progressively used as a country-wide publicly data source, holding much potential and support the assessment of patterns of care and outcomes for research. It allows novel approaches to investigate disease conditions, optimal care, and patient outcomes. The NIS is a stratified weighted sample of discharges from US community hospitals, excluding rehabilitation and long-term acute care facilities. The significance of the weighting is for allowing to produce national estimates of hospitalizations for specific factors, however national estimates were not the focus of this project. This retrospective cohort study extracted data on adult and elderly patients with arterial embolism and thrombosis that had emergency admissions.

The sample extracted from the NIS-2005-2014. The ICD-9 code to identify patients with, was 444. ICD-9 codes for surgical procedures and invasive diagnostic procedures data are presented in Table 1. The following characteristics of patients and hospitals were collected: age, gender, race, income quartile, health care insurance

(Medicare, Medicaid, private insurance, self-paid, and no charge), hospital length of stay (HLOS), mortality rate, location of embolism, total charges and the modified frailty index.

Table 1: Procedures of emergency admitted patients with the primary diagnosis of arterial embolism and thrombosis.

Cardiovascular System Surgical Procedures (ICD 9)

Operations on Valves and Septa of Heart (35.00-35.99)
Operations on Vessels of Heart (36.03-36.99)
Operations on Heart and Pericardium (37.0-37.12, 37.31-37.99)
Operations on Operations of Vessels (38.00-38.18, 38.30-39.99)

Cardiovascular System Invasive Diagnostic Procedure (ICD 9)

Invasive Diagnostic Procedure on Heart and Pericardium (37.20-37.29)
Invasive Diagnostic Procedure on Incision, Excision, and Occlusion of Vessels (38.21-38.29)

A frailty score was calculated using a 5-item modified frailty index. Comorbid diabetes was considered if either 1) comorbidity of diabetes uncomplicated or 2) diabetes with chronic complications was indicated. A past medical history of hypertension, congestive heart failure and chronic obstructive pulmonary disease were included if among the comorbidities. As the functional health status was unavailable in this particular dataset, we instead estimated based on the available variables. Comorbidities including tumor, renal failure, metastatic cancer, paralysis, lymphoma, coagulopathy, or weight loss, were considered partially or totally functionally dependent. Both of these criteria add 1 point to each item if the comorbidity item was present. This total is our estimated modified frailty score. This frailty score ranged from 0 to 5, 0 being not frail and 5 being really frail.

Statistical Analysis

Descriptive and analytical statistical indicators were used to present the findings. Mean, standard deviation (SD), and confidence interval at 95% (CI) were calculated for numerical variables. The comparisons were done by 2 test for categorical variables, and by t-test for continuous variables. The data were first stratified according to elderly vs. nonelderly adults and then, further stratified by male vs. female, survived vs. deceased and operated vs. not operated. The univariable behavior of different variables in predicting the mortality risk was evaluated by logistic regression analysis. Multivariable logistic regression model was used to find the final predictors of mortality in adjusted model through backward stepwise regression analysis. Multivariable regression was adjusted for the following characteristics of patients and hospitals: age, sex, race, income quartile, health care insurance, hospital location, modified frailty index, location of embolism, invasive diagnostic procedures, and time to operation. The basic residual plots were checked to assure good compliance with model assumptions. The p values less than 0.05 were considered significant. All analyses were done by SPSS software version 26 (SPSS Inc., Chicago, IL).

畿

Results Sex Differences

Non-elderly patients

The mean age of the nine patients who died during the study period was 58 (7) years, 5 were males (55.6%) and 4 were females (44.4%), with a similar mean age. Regardless of the gender, most patients were white, funded by private insurance, and were admitted to urban teaching hospitals. Some of the major comorbidities were chronic pulmonary disease and peripheral vascular disorders, among others. Men were more at risk for alcohol abuse and peripheral vascular disorders whereas women were at a higher risk for deficiency anemia, chronic pulmonary disease and obesity. Women were also more likely ot have a longer HLOS. Patient characteristics are summarized in Table 2.

Elderly Patients

The mean age of the 25 patients who died during the study period was 80 (8) years, 8 were males (32.0%) and 17 were females (68.0%), with a similar mean age. Regardless of the gender, most patients were white, funded by Medicare, and were admitted to urban non-teaching hospitals. Men were more likely to suffer from alcohol abuse and uncomplicated diabetes. Women on the other hand were more at risk for hypothyroidism and a longer HLOS.

Mortality

Non-Elderly

0.9% of adult patients died in hospital with a similar demographics and clinical characteristics to those who survived. Coagulopathy and renal failure were the only comorbidities that were more prevalent in deceased compared to survived ones.

Elderly

In elderly patients, 2% died in the hospital. They were four years older than the survived patients (79.56 vs. 75.43 years old) and their time to operation was more than double of those who survived (0.45 vs 1.00 days). The prevalence of comorbidities of coagulopathy, renal failure, liver diseases, weight loss and fluid/electrolyte disorders were significantly higher in deceased vs. survived patients (Table 3).

Operation vs. No Operation

Non-Elderly

The stratified analysis based on operation is presented in Table 4. In adult patients, most clinical and demographic characteristics were similar. Congestive heart failure, valvular diseases and hypothyroidism were significantly more common in non-operated adults than the operated adults which may partly explain why they were not operated on. The operated-on group also was two years younger on average (55 vs 53 years old) and had a longer HLOS by one day (5 vs. 4). In this patient group, all the invasive diagnostic procedure were conducted on the heart and pericardium which comprised ICD-9 codes 37.20-37.29. 99.5% of the surgical oper-

ations were on vessels (ICD-9 codes 38.00-38.18, 38.30-39.99). *Elderly*

Patients were mostly white and at an urban teaching hospital. In elderly patients the rate of comorbidities of congestive heart failure, valvular diseases and solid tumors were significantly more common in non-operated patients than the operated ones which may partly explain why they were not operated. The comorbidities most common in patients that underwent a surgery were chronic pulmonary disease, peripheral vascular disease and hypertension (Table 4). In the elderly patient group, 95.2% of the invasive diagnostic procedures were performed on the heart and pericardium which comprised ICD-9 codes 37.20-37.29. The surgical operations on vessels in this patient group was 98.2%.

Location of Arterial Thromboembolism

Non-Elderly

The stratified analysis based on location of arterial embolism and thrombosis in adult patients is presented in Table 5. More than half of the thromboembolisms/thromboses were located in the lower extremities, followed by abdomen, iliac arteries, upper extremities and thoracic. Patients with a lower extremity thrombosis or thromboembolism were most likely to suffer from uncomplicated diabetes compared to other locations. Those with abdominal clots had the highest likelihood of having a peripheral vascular disease relative to the other places. The modified frailty index was highest for patients with a thoracic clot. The time to surgery was the longest for upper extremity clot patients. The highest mean HLOS was recorded among patients with abdominal arterial thromboembolism followed by upper extremities, and lower extremities.

Elderly

Two-thirds of arterial thromboembolism were found in lower extremities followed by iliac arteries, and abdomen. In those with abdominal clots, chronic pulmonary disease, coagulopathy, peripheral vascular disease and fluid/electrolyte disorders were more likely. Obesity was most common in iliac clot patients. The mean HLOS was highest in patients with abdominal arterial thromboembolism followed by lower and upper extremities (Table 6).

Risk Factors of Mortality

The multivariable logistic regression model for mortality was built for the group with operation. Common variables used to adjust the two models were age, sex, race, income, health care insurance, hospital location, embolism/thrombosis location, invasive diagnostic procedure, modified frailty index and time to operation. In operated patients, the main risk factors of mortality in the final multivariable model were delayed operation and frailty index for adults, and female sex and frailty index for elderly patients (Table 7).

Table 2. Characteristics of emergency admitted patients with the primary diagnosis of arterial embolism and thrombosis. Data was stratified according to sex categories, NIS 2004-2014.

Patients' Char	acteristics	Adult,	N (%)		Elderly	, N (%)	
		Male	Female	р	Male	Female	р
All Cases		624 (59.9%)	417 (40.1%)		642 (51.0%)	618 (49.0%)	
	White	356 (75.4%)	234 (76.2%)		414 (80.9%)	371 (79.4%)	
	Black	67 (14.2%)	51 (16.6%)		41 (8.0%)	46 (9.9%)	
Race	Hispanic	31 (6.6%)	18 (5.9%)	0.260	36 (7.0%)	29 (6.2%)	0.920
	Asian/Pacific Islander	4 (0.8%)	2 (0.7%)		4 (0.8%)	5 (1.1%)	
	Native American	2 (0.4%)	1 (0.3%)		3 (0.6%)	3 (0.6%)	
	Other Quartile 1	12 (2.5%)	1 (0.3%)		14 (2.7%)	13 (2.8%)	
Income	Quartile 1 Quartile 2	196 (32.7%) 166 (27.7%)	145 (35.7%) 120 (29.6%)		188 (29.7%) 175 (27.6%)	184 (30.6%) 163 (27.1%)	
Quartile	Quartile 3	132 (22.0%)	78 (19.2%)	0.490	138 (21.8%)	136 (22.6%)	0.930
Quartile	Quartile 4	105 (17.5%)	63 (15.5%)		133 (21.0%)	119 (19.8%)	
	Private Insurance	374 (60.0%)	222 (53.8%)		64 (10.0%)	44 (7.1%)	
	Medicare	131 (21.0%)	102 (24.7%)		565 (88.3%)	561 (90.8%)	
	Medicaid	57 (9.1%)	64 (15.5%)		3 (0.5%)	8 (1.3%)	
Insurance	Self-Pay	28 (4.5%)	12 (2.9%)	0.007	3 (0.5%)	2 (0.3%)	0.180
	No Charge	2 (0.3%)	1 (0.2%)		0 (0%)	0 (0%)	
	Other	31 (5.0%)	12 (2.9%)		5 (0.8%)	3 (0.5%)	
Usonital	Rural	66 (10.6%)	55 (13.2%)		68 (10.6%)	78 (12.6%)	
Hospital	Urban: Non-Teaching	271 (43.4%)	175 (42.0%)	0.440	314 (48.9%)	271 (43.9%)	0.180
Location	Urban: Teaching	287 (46.0%)	187 (44.8%)		260 (40.5%)	268 (43.4%)	
	AIDS	1 (0.2%)	1 (0.2%)	0.999	0 (0%)	1 (0.2%)	0.490
	Alcohol Abuse	23 (3.7%)	6 (1.4%)	0.034	14 (2.2%)	3 (0.5%)	0.012
	Deficiency Anemias	46 (7.4%)	50 (12.0%)	0.012	77 (12.0%)	73 (11.8%)	0.920
	Rheumatoid Arthritis	8 (1.3%)	12 (2.9%)	0.070	9 (1.4%)	16 (2.6%)	0.130
	Chronic Blood Loss	4 (0.6%)	4 (1.0%)	0.720	7 (1.1%)	10 (1.6%)	0.420
	Congestive Heart Failure	9 (1.4%)	3 (0.7%)	0.380	13 (2.0%)	24 (3.9%)	0.051
	Chronic Pulmonary Disease	149 (23.9%)	127 (30.5%)	0.018	168 (26.2%)	169 (27.3%)	0.640
	Coagulopathy	10 (1.6%)	14 (3.4%)	0.070	18 (2.8%)	19 (3.1%)	0.780
	Depression	22 (3.5%)	30 (7.2%)	0.008	19 (3.0%)	25 (4.0%)	0.290
	Diabetes, Uncomplicated	133 (21.3%)	77 (18.5%)	0.260	197 (30.7%)	134 (21.7%)	<0.001
	Diabetes, Chronic Complications	28 (4.5%)	28 (6.7%)	0.120	42 (6.5%)	35 (5.7%)	0.520
	Drug Abuse	7 (1.1%)	5 (1.2%)	0.910	1 (0.2%)	0 (0%)	0.999
	Hypertension	373 (59.8%)	258 (61.9%)	0.500	442 (68.8%)	449 (72.7%)	0.140
	Hypothyroidism Liver Disease	12 (1.9%)	35 (8.4%)	<0.001	30 (4.7%)	85 (13.8%)	<0.001
Comorbidities	Liver Disease Lymphoma	13 (2.1%)	3 (0.7%)	0.120 0.650	4 (0.6%)	4 (0.6%)	0.999 0.999
	Fluid/Electrolyte Disorders	4 (0.6%)	1 (0.2%) 46 (11.0%)	0.030	3 (0.5%)	3 (0.5%) 71 (11.5%)	0.999
	Metastatic Cancer	41 (6.6%)	5 (1.2%)	0.710	46 (7.2%) 13 (2.0%)	6 (1.0%)	0.130
	Other Neurological Disorders	6 (1.0%) 21 (3.4%)	13 (3.1%)	0.830	13 (2.0%)	27 (4.4%)	0.130
	Obesity	35 (5.6%)	46 (11.0%)	0.001	19 (3.0%)	22 (3.6%)	0.550
	Paralysis	7 (1.1%)	4 (1.0%)	0.999	13 (2.0%)	8 (1.3%)	0.380
	Peripheral Vascular Disorders	340 (54.5%)	195 (46.8%)	0.015	285 (44.4%)	307 (49.7%)	0.060
	Psychoses	7 (1.1%)	7 (1.7%)	0.450	3 (0.5%)	8 (1.3%)	0.140
	Pulmonary Circulation	, ,				250	
	Disorders	0 (0%)	1 (0.2%)	0.400	0 (0%)	3 (0.5%)	0.120
	Renal Failure	40 (6.4%)	28 (6.7%)	0.850	84 (13.1%)	74 (12.0%)	0.550
	Solid Tumor	6 (1.0%)	7 (1.7%)	0.310	15 (2.3%)	10 (1.6%)	0.360
	Peptic Ulcer	0 (0%)	0 (0%)		0 (0%)	0 (0%)	
	Valvular Disease	4 (0.6%)	5 (1.2%)	0.500	9 (1.4%)	7 (1.1%)	0.670
	Waight Lags	7 (1.1%)	7 (1.7%)	0.450	10 (1.6%)	17 (2.8%)	0.140
	Weight Loss		118 (28.3%)		60 (9.3%)	93 (15.0%)	
Fresh a liana /	Abdominal Aorta	128 (20.5%)	110 (20.370)				
	0	128 (20.5%) 0 (0%)	2 (0.5%)	0.005	2 (0.3%)	0 (0%)	<0.001
Thrombosis	Abdominal Aorta			0.005	2 (0.3%) 25 (3.9%)	0 (0%) 45 (7.3%)	<0.001
Thrombosis	Abdominal Aorta Thoracic Aorta	0 (0%)	2 (0.5%)	0.005	•		<0.001
Thrombosis	Abdominal Aorta Thoracic Aorta Upper Extremity	0 (0%) 43 (6.9%)	2 (0.5%) 36 (8.6%)	0.005	25 (3.9%) 444 (69.2%) 111 (17.3%)	45 (7.3%)	<0.001
Thrombosis Location	Abdominal Aorta Thoracic Aorta Upper Extremity Lower Extremity Iliac Artery	0 (0%) 43 (6.9%) 345 (55.3%)	2 (0.5%) 36 (8.6%) 191 (45.8%)	0.005	25 (3.9%) 444 (69.2%)	45 (7.3%) 406 (65.7%)	< 0.001
Thrombosis Location Invasive Diagno Surgical Proced	Abdominal Aorta Thoracic Aorta Upper Extremity Lower Extremity Iliac Artery ostic Procedure	0 (0%) 43 (6.9%) 345 (55.3%) 108 (17.3%)	2 (0.5%) 36 (8.6%) 191 (45.8%) 70 (16.8%) 6 (1.4%) 382 (91.6%)	0.220 0.960	25 (3.9%) 444 (69.2%) 111 (17.3%)	45 (7.3%) 406 (65.7%) 74 (12.0%)	
Thrombosis Location Invasive Diagno Surgical Proced	Abdominal Aorta Thoracic Aorta Upper Extremity Lower Extremity Iliac Artery ostic Procedure	0 (0%) 43 (6.9%) 345 (55.3%) 108 (17.3%) 16 (2.6%) 571 (91.5%) 5 (0.8%)	2 (0.5%) 36 (8.6%) 191 (45.8%) 70 (16.8%) 6 (1.4%) 382 (91.6%) 4 (1.0%)	0.220	25 (3.9%) 444 (69.2%) 111 (17.3%) 12 (1.9%)	45 (7.3%) 406 (65.7%) 74 (12.0%) 9 (1.5%) 532 (86.1%) 17 (2.8%)	0.570
Thrombosis Location Invasive Diagno Surgical Proced	Abdominal Aorta Thoracic Aorta Upper Extremity Lower Extremity Iliac Artery ostic Procedure	0 (0%) 43 (6.9%) 345 (55.3%) 108 (17.3%) 16 (2.6%) 571 (91.5%)	2 (0.5%) 36 (8.6%) 191 (45.8%) 70 (16.8%) 6 (1.4%) 382 (91.6%)	0.220 0.960 0.999 p	25 (3.9%) 444 (69.2%) 111 (17.3%) 12 (1.9%) 578 (90.0%)	45 (7.3%) 406 (65.7%) 74 (12.0%) 9 (1.5%) 532 (86.1%) 17 (2.8%) Mean (SD)	0.570 0.031 0.060 p
Thrombosis Location Invasive Diagno Surgical Proced Deceased Age, Years	Abdominal Aorta Thoracic Aorta Upper Extremity Lower Extremity Iliac Artery ostic Procedure	0 (0%) 43 (6.9%) 345 (55.3%) 108 (17.3%) 16 (2.6%) 571 (91.5%) 5 (0.8%)	2 (0.5%) 36 (8.6%) 191 (45.8%) 70 (16.8%) 6 (1.4%) 382 (91.6%) 4 (1.0%)	0.220 0.960 0.999 p 0.910	25 (3.9%) 444 (69.2%) 111 (17.3%) 12 (1.9%) 578 (90.0%) 8 (1.2%)	45 (7.3%) 406 (65.7%) 74 (12.0%) 9 (1.5%) 532 (86.1%) 17 (2.8%)	0.570 0.031 0.060 p < 0.001
Thrombosis Location Invasive Diagno Surgical Proced Deceased Age, Years Time to Invasiv	Abdominal Aorta Thoracic Aorta Upper Extremity Lower Extremity Iliac Artery ostic Procedure lure	0 (0%) 43 (6.9%) 345 (55.3%) 108 (17.3%) 16 (2.6%) 571 (91.5%) 5 (0.8%) Mean (SD) 54.79 (6.85) 1.29 (1.68)	2 (0.5%) 36 (8.6%) 191 (45.8%) 70 (16.8%) 6 (1.4%) 382 (91.6%) 4 (1.0%) Mean (SD) 54.26 (8.02) 0.75 (1.50)	0.220 0.960 0.999 p 0.910 0.570	25 (3.9%) 444 (69.2%) 111 (17.3%) 12 (1.9%) 578 (90.0%) 8 (1.2%) Mean (SD) 74.34 (6.66) 2.56 (3.81)	45 (7.3%) 406 (65.7%) 74 (12.0%) 9 (1.5%) 532 (86.1%) 17 (2.8%) Mean (SD) 76.73 (7.69) 0.33 (0.52)	0.570 0.031 0.060 p <0.001 0.330
Thrombosis Location Invasive Diagno Surgical Proced Deceased Age, Years Time to Invasiv Time to Surgica	Abdominal Aorta Thoracic Aorta Upper Extremity Lower Extremity Iliac Artery ostic Procedure lure The Diagnostic Procedure, Days al Procedure, Days	0 (0%) 43 (6.9%) 345 (55.3%) 108 (17.3%) 16 (2.6%) 571 (91.5%) 5 (0.8%) Mean (SD) 54.79 (6.85) 1.29 (1.68) 0.38 (1.25)	2 (0.5%) 36 (8.6%) 191 (45.8%) 70 (16.8%) 6 (1.4%) 382 (91.6%) 4 (1.0%) Mean (SD) 54.26 (8.02) 0.75 (1.50) 0.55 (1.63)	0.220 0.960 0.999 p 0.910 0.570 0.490	25 (3.9%) 444 (69.2%) 111 (17.3%) 12 (1.9%) 578 (90.0%) 8 (1.2%) Mean (SD) 74.34 (6.66) 2.56 (3.81) 0.48 (2.43)	45 (7.3%) 406 (65.7%) 74 (12.0%) 9 (1.5%) 532 (86.1%) 17 (2.8%) Mean (SD) 76.73 (7.69) 0.33 (0.52) 0.44 (1.23)	0.570 0.031 0.060 p <0.001 0.330 0.180
Thrombosis Location Invasive Diagno Surgical Proced Deceased Age, Years Time to Invasiv Time to Surgica Modified Frailt	Abdominal Aorta Thoracic Aorta Upper Extremity Lower Extremity Iliac Artery ostic Procedure lure The Diagnostic Procedure, Days al Procedure, Days y Index Score	0 (0%) 43 (6.9%) 345 (55.3%) 108 (17.3%) 16 (2.6%) 571 (91.5%) 5 (0.8%) Mean (SD) 54.79 (6.85) 1.29 (1.68) 0.38 (1.25) 1.23 (0.96)	2 (0.5%) 36 (8.6%) 191 (45.8%) 70 (16.8%) 6 (1.4%) 382 (91.6%) 4 (1.0%) Mean (SD) 54.26 (8.02) 0.75 (1.50) 0.55 (1.63) 1.32 (0.89)	0.220 0.960 0.999 p 0.910 0.570 0.490 0.120	25 (3.9%) 444 (69.2%) 111 (17.3%) 12 (1.9%) 578 (90.0%) 8 (1.2%) Mean (SD) 74.34 (6.66) 2.56 (3.81) 0.48 (2.43) 1.56 (0.94)	45 (7.3%) 406 (65.7%) 74 (12.0%) 9 (1.5%) 532 (86.1%) 17 (2.8%) Mean (SD) 76.73 (7.69) 0.33 (0.52) 0.44 (1.23) 1.51 (0.94)	0.570 0.031 0.060 p <0.001 0.330 0.180 0.350
	Abdominal Aorta Thoracic Aorta Upper Extremity Lower Extremity Iliac Artery ostic Procedure lure The Diagnostic Procedure, Days al Procedure, Days y Index Score	0 (0%) 43 (6.9%) 345 (55.3%) 108 (17.3%) 16 (2.6%) 571 (91.5%) 5 (0.8%) Mean (SD) 54.79 (6.85) 1.29 (1.68) 0.38 (1.25)	2 (0.5%) 36 (8.6%) 191 (45.8%) 70 (16.8%) 6 (1.4%) 382 (91.6%) 4 (1.0%) Mean (SD) 54.26 (8.02) 0.75 (1.50) 0.55 (1.63)	0.220 0.960 0.999 p 0.910 0.570 0.490	25 (3.9%) 444 (69.2%) 111 (17.3%) 12 (1.9%) 578 (90.0%) 8 (1.2%) Mean (SD) 74.34 (6.66) 2.56 (3.81) 0.48 (2.43)	45 (7.3%) 406 (65.7%) 74 (12.0%) 9 (1.5%) 532 (86.1%) 17 (2.8%) Mean (SD) 76.73 (7.69) 0.33 (0.52) 0.44 (1.23)	0.031 0.060 p <0.001 0.330 0.180



Table 3. Characteristics of emergency admitted patients with the primary diagnosis of arterial embolism and thrombosis. Data was classified according to outcome categories, NIS 2004-2014

Patients' Char	racteristics	Adult,		р		r, N (%)	р
		Survived	Deceased		Survived	Deceased	
All Cases		1,033 (99.1%)	9 (0.9%)	0.000	1,235 (98.0%)	25 (2.0%)	0.000
Sex, Female	NATE:	413 (40.1%)	4 (44.4%)	0.999	601 (48.7%)	17 (68.0%)	0.060
	White	584 (75.7%)	5 (71.4%)		771 (80.3%)	14 (73.7%)	
	Black	116 (15.0%)	2 (28.6%)		84 (8.8%)	3 (15.8%)	
Race	Hispanic	49 (6.4%)	0 (0%)	0.910	64 (6.7%)	1 (5.3%)	0.120
	Asian/Pacific Islander	6 (0.8%)	0 (0%)		9 (0.9%)	0 (0%)	
	Native American	3 (0.4%)	0 (0%)		5 (0.5%)	1 (5.3%)	
	Other	13 (1.7%)	0 (0%)		27 (2.8%)	0 (0%)	
Income	Quartile 1	340 (34.1%)	1 (11.1%)		361 (29.8%)	11 (44.0%)	
Quartile	Quartile 2	284 (28.5%)	2 (22.2%)	0.250	329 (27.2%)	9 (36.0%)	0.100
Quartile	Quartile 3 Quartile 4	206 (20.6%)	4 (44.4%)		273 (22.5%)	1 (4.0%) 4 (16.0%)	
	Private Insurance	168 (16.8%) 593 (57.7%)	2 (22.2%) 5 (55.6%)		248 (20.5%) 105 (8.5%)	3 (12.0%)	
	Medicare	229 (22.3%)	4 (44.4%)		1,104 (89.5%)	22 (88.0%)	
	Medicaid	120 (11.7%)	0 (0%)		11 (0.9%)	0 (0%)	
nsurance	Self-Pay	40 (3.9%)	0 (0%)	0.580	5 (0.4%)	0 (0%)	0.930
	No Charge	3 (0.3%)	0 (0%)		0 (0%)	0 (0%)	
	Other	43 (4.2%)	0 (0%)		8 (0.6%)	0 (0%)	
	Rural	120 (11.6%)	1 (11.1%)		146 (11.8%)	0 (0%)	
Hospital	Urban: Non-Teaching	442 (42.8%)	6 (66.7%)	0.320	571 (46.3%)	14 (56.0%)	0.180
Location	Urban: Teaching			0.320	517 (41.9%)	11 (44.0%)	0.180
	AIDS	471 (45.6%) 2 (0.2%)	2 (22.2%) 0 (0%)	0.999	1 (0.1%)	0 (0%)	0.999
	Alcohol Abuse		0 (0%)	0.999			0.999
		29 (2.8%)	2 (22.2%)		16 (1.3%)	1 (4.0%)	
	Deficiency Anemias	94 (9.1%)		0.200	146 (11.8%)	4 (16.0%)	0.530
	Rheumatoid Arthritis	20 (1.9%)	0 (0%)	0.999	25 (2.0%)	0 (0%)	0.999
	Chronic Blood Loss	8 (0.8%)	0 (0%)	0.999	15 (1.2%)	2 (8.0%)	0.043
	Congestive Heart Failure	11 (1.1%)	1 (11.1%)	0.100	35 (2.8%)	2 (8.0%)	0.170
	Chronic Pulmonary Disease	272 (26.3%)	3 (33.3%)	0.710	327 (26.5%)	10 (40.0%)	0.130
	Coagulopathy	22 (2.1%)	2 (22.2%)	0.017	32 (2.6%)	5 (20.0%)	<0.001
	Depression	52 (5.0%)	0 (0%)	0.999	44 (3.6%)	0 (0%)	0.999
	Diabetes, Uncomplicated	208 (20.1%)	2 (22.2%)	0.999	327 (26.5%)	4 (16.0%)	0.360
	Diabetes, Chronic Complications	56 (5.4%)	0 (0%)	0.999	75 (6.1%)	2 (8.0%)	0.660
	Drug Abuse	12 (1.2%)	0 (0%)	0.999	1 (0.1%)	0 (0%)	0.999
	Hypertension	626 (60.6%)	4 (44.4%)	0.330	877 (71.0%)	14 (56.0%)	0.100
	Hypothyroidism	46 (4.5%)	1 (11.1%)	0.340	113 (9.1%)	2 (8.0%)	0.999
Comorbidities	Liver Disease	15 (1.5%)	1 (11.1%)	0.130	6 (0.5%)	2 (8.0%)	0.010
	Lymphoma	5 (0.5%)	0 (0%)	0.999	6 (0.5%)	0 (0%)	0.999
	Fluid/Electrolyte Disorders	85 (8.2%)	2 (22.2%)	0.170	108 (8.7%)	9 (36.0%)	<0.001
	Metastatic Cancer	11 (1.1%)	0 (0%)	0.999	19 (1.5%)	0 (0%)	0.999
	Other Neurological Disorders	34 (3.3%)	0 (0%)	0.999	38 (3.1%)	2 (8.0%)	0.190
	Obesity	81 (7.8%)	0 (0%)	0.999	41 (3.3%)	0 (0%)	0.999
	Paralysis	11 (1.1%)	0 (0%)	0.999	21 (1.7%)	0 (0%)	0.999
	Peripheral Vascular Disorders	529 (51.2%)	6 (66.7%)	0.510	580 (47.0%)	12 (48.0%)	0.920
	Psychoses	14 (1.4%)	0 (0%)	0.999	11 (0.9%)	0 (0%)	0.999
	Pulmonary Circulation	1 (0.1%)	0 (0%)	0.999	3 (0.2%)	0 (0%)	0.999
	Disorders						
	Renal Failure	65 (6.3%)	3 (33.3%)	0.017	151 (12.2%)	7 (28.0%)	0.018
	Solid Tumor	13 (1.3%)	0 (0%)	0.999	24 (1.9%)	1 (4.0%)	0.400
	Peptic Ulcer	0 (0%)	0 (0%)		0 (0%)	0 (0%)	
	Valvular Disease	8 (0.8%)	1 (11.1%)	0.080	15 (1.2%)	1 (4.0%)	0.280
	Weight Loss	14 (1.4%)	0 (0%)	0.999	23 (1.9%)	4 (16.0%)	0.002
Embolism/	Abdominal Aorta	242 (23.4%)	4 (44.4%)		146 (11.8%)	7 (28.0%)	
Thrombosis	Thoracic Aorta	2 (0.2%)	0 (0%)	0.260	2 (02%)	0 (0%)	0.160
Location	Upper Extremity	79 (7.6%)	0 (0%)		68 (5.5%)	2 (8.0%)	
	Lower Extremity	534 (51.7%)	2 (22.2%)		837 (67.8%)	13 (52.0%)	
	Iliac Artery	176 (17.0%)	3 (33.3%)	2000	182 (14.7%)	3 (12.0%)	
	ostic Procedure	22 (2.1%)	0 (0%)	0.999	18 (1.5%)	3 (12.0%)	0.007
Surgical Proced	dure	945 (91.5%)	9 (100%)	0.999	1,089 (88.2%)	21 (84.0%)	0.530
		Mean (SD)	Mean (SD)	р	Mean (SD)	Mean (SD)	р
Age, Years		54.53 (7.36)	57.67 (4.72)	0.230	75.43 (7.24)	79.56 (8.36)	0.014
	ve Diagnostic Procedure, Days	1.17 (1.62)	-(-)		1.58 (3.18)	2.00 (3.46)	0.950
	al Procedure, Days	0.45 (1.42)	0.63 (0.92)	0.130	0.45 (1.97)	1.00 (1.48)	0.002
Modified Frailt	ty Index Score	1.26 (0.93)	1.67 (1.00)	0.200	1.53 (0.94)	1.88 (1.05)	0.070
Hospital Lengt	h of Stay, Days	4.63 (4.75)	3.44 (3.58)	0.270	4.88 (5.96)	6.28 (7.10)	0.700
Total Charges,	Dollars	47,481	74,895	0.003	48,706	99,400	0.021
iotai Charges,	Donal 3	(45,066)	(28,306)	0.003	(48,244)	(107,564)	0.021

Table 4. Characteristics of emergency admitted patients with the primary diagnosis of arterial embolism and thrombosis. Data was stratified according to operation status, NIS 2004-2014.

Patients' Char	acteristics	Adult,	N (%)		Elderl	y, N (%)	(m)
		No Operation	Operation	р	No Operation	Operation	р
All Cases		88 (8.4%)	955 (91.6%)		150 (11.9%)	1,110 (88.1%)	
Sex, Female		35 (39.8%)	382 (40.1%)	0.999	86 (57.3%)	532 (47.9%)	0.031
	White	50 (79.4%)	540 (75.4%)		84 (75.7%)	701 (80.8%)	
	Black	8 (12.7%)	110 (15.4%)		6 (5.4%)	81 (9.3%)	
Race	Hispanic	3 (4.8%)	46 (6.4%)	0.590	11 (9.9%)	54 (6.2%)	0.048
1000	Asian/Pacific Islander	0 (0%)	6 (0.8%)	0.550	2 (1.8%)	7 (0.8%)	0.010
	Native American	1 (1.6%)	2 (0.3%)		2 (1.8%)	4 (0.5%)	
	Other	1 (1.6%)	12 (1.7%)		6 (5.4%)	21 (2.4%)	
	Quartile 1	22 (26.5%)	319 (34.5%)		53 (36.3%)	319 (29.3%)	
ncome	Quartile 2	30 (36.1%)	256 (27.7%)	0.280	42 (28.8%)	296 (27.2%)	0.200
Quartile	Quartile 3	19 (22.9%)	191 (20.7%)		28 (19.2%)	246 (22.6%)	
	Quartile 4	12 (14.5%)	158 (17.1%)		23 (15.8%)	229 (21.0%)	
	Private Insurance	50 (58.1%)	548 (57.6%)		9 (6.0%)	99 (8.9%)	
	Medicare	21 (24.4%)	212 (22.3%)		137 (91.9%)	989 (89.2%)	
nsurance	Medicaid	5 (5.8%)	116 (12.2%)	0.170	1 (0.7%)	10 (0.9%)	0.770
	Self-Pay	7 (8.1%)	33 (3.5%)	0.270	1 (0.7%)	4 (0.4%)	0.,,
	No Charge	0 (0%)	3 (0.3%)		0 (0%)	0 (0%)	
	Other	3 (3.5%)	40 (4.2%)		1 (0.7%)	7 (0.6%)	
lospital	Rural	9 (10.2%)	112 (11.7%)		31 (20.8%)	115 (10.4%)	
ocation	Urban: Non-Teaching	45 (51.1%)	403 (42.2%)	0.270	51 (34.2%)	534 (48.1%)	<0.00
	Urban: Teaching	34 (38.6%)	440 (46.1%)		67 (45.0%)	461 (41.5%)	
	AIDS	0 (0%)	2 (0.2%)	0.999	0 (0%)	1 (0.1%)	0.999
	Alcohol Abuse	1 (1.1%)	28 (2.9%)	0.500	0 (0%)	17 (1.5%)	0.250
	Deficiency Anemias	11 (12.5%)	85 (8.9%)	0.260	15 (10.0%)	135 (12.2%)	0.440
	Rheumatoid Arthritis	3 (3.4%)	17 (1.8%)	0.230	7 (4.7%)	18 (1.6%)	0.012
	Chronic Blood Loss	0 (0%)	8 (0.8%)	0.999	3 (2.0%)	14 (1.3%)	0.440
	Congestive Heart Failure	8 (9.1%)	4 (0.4%)	<0.001	26 (17.3%)	11 (1.0%)	<0.00
	Chronic Pulmonary Disease	14 (15.9%)	262 (27.4%)	0.019	28 (18.7%)	309 (27.8%)	0.01
	Coagulopathy	3 (3.4%)	21 (2.2%)	0.450	1 (0.7%)	36 (3.2%)	0.120
	Depression	5 (5.7%)	47 (4.9%)	0.750	7 (4.7%)	37 (3.3%)	0.400
	Diabetes, Uncomplicated	18 (20.5%)	192 (20.1%)	0.940	33 (22.0%)	298 (26.8%)	0.210
	Diabetes, Chronic Complications	5 (5.7%)	51 (5.3%)	0.890	11 (7.3%)	66 (5.9%)	0.510
	Drug Abuse	2 (2.3%)	10 (1.0%)	0.270	0 (0%)	1 (0.1%)	0.999
	Hypertension	51 (58.0%)	580 (60.7%)	0.610	86 (57.3%)	805 (72.5%)	<0.00
	Hypothyroidism	8 (9.1%)	39 (4.1%)	0.030	14 (9.3%)	101 (9.1%)	0.930
omorbidities	Liver Disease	2 (2.3%)	14 (1.5%)	0.640	1 (0.7%)	7 (0.6%)	0.999
omorbianes	Lymphoma	0 (0%)	5 (0.5%)	0.999	1 (0.7%)	5 (0.5%)	0.530
	Fluid/Electrolyte Disorders	8 (9.1%)	79 (8.3%)	0.790	9 (6.0%)	108 (9.7%)	0.140
	Metastatic Cancer	2 (2.3%)	9 (0.9%)	0.240	5 (3.3%)	14 (1.3%)	0.051
	Other Neurological Disorders	5 (5.7%)	29 (3.0%)	0.200	3 (2.0%)	37 (3.3%)	0.620
	Obesity	9 (10.2%)	72 (7.5%)	0.370	5 (3.3%)	36 (3.2%)	0.950
	Paralysis	1 (1.1%)	10 (1.0%)	0.999	6 (4.0%)	15 (1.4%)	0.017
	Peripheral Vascular Disorders	8 (9.1%)	527 (55.2%)	<0.001	9 (6.0%)	583 (52.5%)	<0.00
	Psychoses	2 (2.3%)	12 (1.3%)	0.330	5 (3.3%)	6 (0.5%)	0.00
	Pulmonary Circulation	0 (0%)	1 (0.1%)	0.999	2 (1.3%)	1 (0.1%)	0.039
	Disorders	0 (0%)	1 (0.1%)	0.999	2 (1.5%)	1 (0.1%)	0.053
	Renal Failure	9 (10.2%)	59 (6.2%)	0.140	20 (13.3%)	138 (12.4%)	0.750
	Solid Tumor	2 (2.3%)	11 (1.2%)	0.300	8 (5.3%)	17 (1.5%)	0.002
	Peptic Ulcer	0 (0%)	0 (0%)		0 (0%)	0 (0%)	
	Valvular Disease	3 (3.4%)	6 (0.6%)	0.034	10 (6.7%)	6 (0.5%)	<0.00
	Weight Loss	2 (2.3%)	12 (1.3%)	0.330	7 (4.7%)	20 (1.8%)	0.023
mbolism/	Abdominal Aorta	9 (10.2%)	237 (24.8%)		6 (4.0%)	147 (13.2%)	
hrombosis	Thoracic Aorta	2 (2.3%)	0 (0%)	<0.001	1 (0.7%)	1 (0.1%)	<0.00
cation	Upper Extremity	15 (17.0%)	64 (6.7%)		23 (15.3%)	47 (4.2%)	
	Lower Extremity	54 (61.4%)	483 (50.6%)		108 (72.0%)	742 (66.8%)	
	Iliac Artery	8 (9.1%)	171 (17.9%)		12 (8.0%)	173 (15.6%)	
vasive Diagno	ostic Procedure	9 (10.2%)	13 (1.4%)	< 0.001	2 (1.3%)	19 (1.7%)	0.999
eceased		0 (0%)	9 (0.9%)	0.999	4 (2.7%)	21 (1.9%)	0.530
		Mean (SD)	Mean (SD)	р	Mean (SD)	Mean (SD)	р
ge, Years		52.68 (8.58)	54.74 (7.20)	0.045	78.34 (8.05)	75.13 (7.09)	<0.00
0 /	e Diagnostic Procedure, Days	0.88 (1.13)	1.40 (1.96)	0.900	0.50 (0.71)	1.85 (3.31)	0.999
	y Index Score	1.30 (1.11)	1.26 (0.92)	0.760	1.50 (1.07)	1.54 (0.92)	0.650
	h of Stay, Days	3.86 (3.89)	4.69 (4.80)	0.033	4.22 (4.45)	5.00 (6.16)	0.14
	J , J						
otal Charges,	D II	20,480	50,247	< 0.001	19,645	53,742	< 0.00



Table 5: Characteristics of emergency admitted adult patients by location of the primary EGS diagnosis arterial embolism and thrombosis, NIS 2004-2014.

Patients' Char	racteristics		Location of A	rterial Embolism/	Thrombosis, N (%)		p
		Abdominal	Thoracic	Upper Extremity	Lower Extremity	Iliac	
II Cases		246 (23.6%)	2 (0.2%)	79 (7.6%)	537 (51.5%)	179 (17.2%)	
ex, Female		118 (48.0%)	2 (100%)	36 (45.6%)	191 (35.6%)	70 (39.3%)	0.00
	White	146 (81.1%)	0 (0%)	48 (80.0%)	292 (70.2%)	104 (84.6%)	
	Black	22 (12.2%)	0 (0%)	7 (11.7%)	78 (18.8%)	11 (8.9%)	
Race	Hispanic	7 (3.9%)	0 (0%)	4 (6.7%)	34 (8.2%)	4 (3.3%)	0.17
	Asian/Pacific Islander	2 (1.1%)	0 (0%)	0 (0%)	3 (0.7%)	1 (0.8%)	0.2.
	Native American	0 (0%)	0 (0%)	0 (0%)	2 (0.5%)	1 (0.8%)	
	Other	3 (1.7%)	0 (0%)	1 (1.7%)	7 (1.7%)	2 (1.6%)	
	Quartile 1	97 (40.8%)	0 (0%)	15 (19.7%)	179 (34.6%)	50 (28.9%)	
ncome	Quartile 2	65 (27.3%)	0 (0%)	22 (28.9%)	146 (28.2%)	53 (30.6%)	0.0
uartile	Quartile 3	44 (18.5%)	2 (100%)	18 (23.7%)	111 (21.4%)	35 (20.2%)	0.0
	Quartile 4	32 (13.4%)	0 (0%)	21 (27.6%)	82 (15.8%)	35 (20.2%)	
	Private Insurance	140 (57.1%)	2 (100%)	48 (60.8%)	302 (56.7%)	106 (59.2%)	
	Medicare	48 (19.6%)	0 (0%)	12 (15.2%)	130 (24.4%)	43 (24.0%)	
nsurance	Medicaid	37 (15.1%)	0 (0%)	10 (12.7%)	56 (10.5%)	18 (10.1%)	0.7
isui ancc	Self-Pay	12 (4.9%)	0 (0%)	3 (3.8%)	20 (3.8%)	5 (2.8%)	0.7
	No Charge	1 (0.4%)	0 (0%)	0 (0%)	2 (0.4%)	0 (0%)	
	Other	7 (2.9%)	0 (0%)	6 (7.6%)	23 (4.3%)	7 (3.9%)	
acnital	Rural	31 (12.6%)	0 (0%)	3 (3.8%)	61 (11.4%)	26 (14.5%)	
ospital	Urban: Non-Teaching	106 (43.1%)	2 (100%)	37 (46.8%)	232 (43.2%)	71 (39.7%)	0.3
cation	Urban: Teaching	109 (44.3%)	0 (0%)	39 (49.4%)	244 (45.4%)	82 (45.8%)	
	AIDS	2 (0.8%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0.1
	Alcohol Abuse	11 (4.5%)	0 (0%)	0 (0%)	14 (2.6%)	4 (2.2%)	0.2
	Deficiency Anemias	30 (12.2%)	0 (0%)	7 (8.9%)	45 (8.4%)	14 (7.8%)	0.4
	Rheumatoid Arthritis	1 (0.4%)	0 (0%)	4 (5.1%)	13 (2.4%)	2 (1.1%)	0.0
	Chronic Blood Loss	3 (1.2%)	0 (0%)	1 (1.3%)	3 (0.6%)	1 (0.6%)	0.8
	Congestive Heart Failure	1 (0.4%)	0 (0%)	1 (1.3%)	8 (1.5%)	2 (1.1%)	0.7
	Chronic Pulmonary Disease	95 (38.6%)	2 (100%)	15 (19.0%)	118 (22.0%)	46 (25.7%)	<0.
	Coagulopathy	9 (3.7%)	0 (0%)	1 (1.3%)	7 (1.3%)	7 (3.9%)	0.
	Depression	8 (3.3%)	0 (0%)	3 (3.8%)	29 (5.4%)	12 (6.7%)	0.5
	Diabetes, Uncomplicated	30 (12.2%)	0 (0%)	12 (15.2%)	140 (26.1%)	28 (15.6%)	<0.
	Diabetes, Chronic	30 (12.270)	0 (076)	12 (13.270)	140 (20.170)	28 (13.0%)	\0.
	Complications	7 (2.8%)	0 (0%)	4 (5.1%)	40 (7.4%)	5 (2.8%)	0.0
	Drug Abuse	2 (0.8%)	0 (0%)	1 (1.3%)	6 (1 1%)	3 (1.7%)	0.9
	Hypertension	151 (61.4%)	1 (50.0%)	41 (51.9%)	6 (1.1%) 342 (63.7%)	96 (53.6%)	0.0
	Hypothyroidism	14 (5.7%)	0 (0%)	2 (2.5%)	25 (4.7%)	6 (3.4%)	0.7
omorbidities	Liver Disease	4 (1.6%)	0 (0%)	2 (2.5%)	6 (1.1%)	4 (2.2%)	0.7
	Lymphoma	2 (0.8%)	0 (0%)	1 (1.3%)	2 (0.4%)	0 (0%)	0.0
	Fluid/Electrolyte Disorders	42 (17.1%)	1 (50.0%)	8 (10.1%)	27 (5.0%)	9 (5.0%)	<0.
	Metastatic Cancer	1 (0.4%)	0 (0%)	4 (5.1%)	5 (0.9%)	1 (0.6%)	0.0
	Other Neurological Disorders	10 (4.1%)	0 (0%)	1 (1.3%)	18 (3.4%)	5 (2.8%)	0.
	Obesity	16 (6.5%)	0 (0%)	13 (16.5%)	43 (8.0%)	9 (5.0%)	0.0
	Paralysis	6 (2.4%)	0 (0%)	1 (1.3%)	3 (0.6%)	1 (0.6%)	0.
	Peripheral Vascular Disorders	155 (63.0%)	0 (0%)	19 (24.1%)	260 (48.4%)	101 (56.4%)	<0.
	Psychoses	7 (2.8%)	0 (0%)	0 (0%)	6 (1.1%)	1 (0.6%)	0.
	Pulmonary Circulation	0 (0%)	0 (0%)	0 (0%)	1 (0.2%)	0 (0%)	0.9
	Disorders	E) E	(3) (3).	-153 51 -1138 No	1274 (2007) 1000 (2007)	10 No. 10	0
	Renal Failure	7 (2.8%)	1 (50.0%)	7 (8.9%)	49 (9.1%)	4 (2.2%)	<0.
	Solid Tumor	4 (1.6%)	0 (0%)	1 (1.3%)	4 (0.7%)	4 (2.2%)	0.3
	Peptic Ulcer	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
	Valvular Disease	0 (0%)	2 (100%)	2 (2.5%)	5 (0.9%)	0 (0%)	<0.
	Weight Loss	10 (4.1%)	0 (0%)	1 (1.3%)	2 (0.4%)	1 (0.6%)	0.0
vasive Diagnos	stic Procedure	4 (1.6%)	0 (0%)	0 (0%)	14 (2.6%)	4 (2.2%)	0.0
rgical Procedi	ure	237 (96.3%)	0 (0%)	64 (81.0%)	483 (89.9%)	171 (95.5%)	<0
vasive or Surg	gical Procedure	240 (97.6%)	0 (0%)	64 (81.0%)	487 (90.7%)	173 (96.6%)	<0.
eceased		4 (1.6%)	0 (0%)	0 (0%)	2 (0.4%)	3 (1.7%)	0.
		Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	Mean (SD)	
ge, Years		55.03 (6.61)	62.00 (-)	48.80 (10.23)	54.90 (7.11)	55.38 (6.40)	<0
Iodified Frailty	y Index Score	1.30 (0.90)	2.00 (1.41)	1.11 (0.89)	1.33 (0.97)	1.07 (0.86)	0.
	e Diagnostic Procedure, Days	0.75 (0.96)	-(-)	-(-)	1.64 (1.86)	0 (0)	0.
		0.45 (1.65)	-(-)	0.77 (1.81)	0.50 (1.42)	0.16 (0.63)	0.
		0.75 (1.05)	(-)	0.77 (1.01)	0.50 (1.42)	0.10 (0.03)	υ.
ime to Surgica			1.00(0)	4 15 (4 52)	4 01 (4 30)	3 48 (3 22)	~ 0
ime to Surgica Iospital Length otal Charges, l	of Stay, Days	6.96 (5.78) 61,517	1.00 (0) 10,519	4.15 (4.52) 30,349	4.01 (4.30) 46,439	3.48 (3.22) 40,674	<0 <0

Table 6: Characteristics of emergency admitted elderly patients by location of the primary EGS diagnosis arterial embolism and
 thrombosis, NIS 2004-2014.

Patients' Char	acteristics	1012 121 441 177			hrombosis, N (%)		p
		Abdominal	Thoracic	Upper Extremity	Lower Extremity	Iliac	
II Cases		153 (12.1%)	2 (0.2%)	70 (5.6%)	850 (67.5%)	185 (14.7%)	
ex, Female		93 (60.8%)	0 (0%)	45 (64.3%)	406 (47.8%)	74 (40.0%)	<0.00
	White	103 (82.4%)	1 (100%)	339 (79.6%)	518 (78.1%)	124 (87.9%)	
	Black	12 (9.6%)	0 (0%)	6 (12.2%)	61 (9.2%)	8 (5.7%)	
Race	Hispanic	4 (3.2%)	0 (0%)	3 (6.1%)	54 (8.1%)	4 (2.8%)	0.76
Cucc	Asian/Pacific Islander	2 (1.6%)	0 (0%)	0 (0%)	5 (0.8%)	2 (1.4%)	0.70
	Native American	1 (0.8%)	0 (0%)	0 (0%)	4 (0.6%)	1 (0.7%)	
	Other	3 (2.4%)	0 (0%)	1 (2.0%)	21 (3.2%)	2 (1.4%)	
	Quartile 1	42 (28.8%)	2 (100%)	25 (35.7%)	255 (30.5%)	48 (26.2%)	
ncome	Quartile 2	41 (28.1%)	0 (0%)	13 (18.6%)	231 (27.7%)	53 (29.0%)	0.44
Quartile	Quartile 3	37 (25.3%)	0 (0%)	13 (18.6%)	182 (21.8%)	42 (23.0%)	0.44
	Quartile 4	26 (17.8%)	0 (0%)	19 (27.1%)	167 (20.0%)	40 (21.9%)	
	Private Insurance	16 (10.5%)	0 (0%)	5 (7.1%)	67 (7.9%)	20 (10.8%)	
	Medicare	131 (85.6%)	2 (100%)	65 (92.9%)	768 (90.6%)	160 (86.5%)	
nsurance	Medicaid	2 (1.3%)	0 (0%)	0 (0%)	8 (0.9%)	1 (0.5%)	0.60
isurance	Self-Pay	2 (1.3%)	0 (0%)	0 (0%)	2 (0.2%)	1 (0.5%)	0.60
	No Charge	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
	Other	2 (1.3%)	0 (0%)	0 (0%)	3 (0.4%)	3 (1.6%)	
ocnita!	Rural	15 (9.8%)	2 (100%)	7 (10.1%)	111 (13.1%)	11 (5.9%)	
ospital	Urban: Non-Teaching	83 (54.2%)	0 (0%)	28 (40.6%)	389 (45.8%)	85 (45.9%)	< 0.0
ocation	Urban: Teaching	55 (35.9%)	0 (0%)	34 (49.3%)	350 (41.2%)	89 (48.1%)	
	AIDS	0 (0%)	0 (0%)	0 (0%)	1 (0.1%)	0 (0%)	0.98
	Alcohol Abuse	2 (1.3%)	0 (0%)	0 (0%)	12 (1.4%)	3 (1.6%)	0.89
	Deficiency Anemias	22 (14.4%)	0 (0%)	8 (11.4%)	98 (11.5%)	22 (11.9%)	0.86
	Rheumatoid Arthritis	4 (2.6%)	0 (0%)	2 (2.9%)	17 (2.0%)	2 (1.1%)	0.84
	Chronic Blood Loss	4 (2.6%)	0 (0%)	2 (2.9%)	8 (0.9%)	3 (1.6%)	0.38
	Congestive Heart Failure	1 (0.7%)	0 (0%)	3 (4.3%)	30 (3.5%)	3 (1.6%)	0.24
	Chronic Pulmonary Disease	67 (43.8%)	0 (0%)	11 (15.7%)	199 (23.4%)	60 (32.4%)	<0.0
	Coagulopathy	10 (6.5%)	0 (0%)	1 (1.4%)	24 (2.8%)	2 (1.1%)	0.0
	Depression	4 (2.6%)	0 (0%)	3 (4.3%)	31 (3.6%)	6 (3.2%)	0.9
	Diabetes, Uncomplicated	35 (22.9%)	1 (50.0%)	17 (24.3%)	235 (27.6%)	43 (23.2%)	0.50
	Diabetes, Chronic	33 (22.370)	1 (50.070)	17 (24.570)	255 (27.070)	45 (25.270)	0.50
	Complications	6 (3.9%)	0 (0%)	3 (4.3%)	60 (7.1%)	8 (4.3%)	0.38
	Drug Abuse	0 (0%)	0 (0%)	0 (0%)	1 (0.1%)	0 (0%)	0.98
	Hypertension	108 (70.6%)	1 (50.0%)	48 (68.6%)	608 (71.5%)	126 (68.1%)	0.84
	Hypothyroidism	16 (10.5%)	0 (0%)	10 (14.3%)	78 (9.2%)	11 (5.9%)	0.28
omorbidities	Liver Disease		0 (0%)	0 (0%)	6 (0.7%)	0 (0%)	0.59
omor bidities		2 (1.3%)					0.00
	Lymphoma	1 (0.7%)	0 (0%)	1 (1.4%)	1 (0.1%)	3 (1.6%)	
	Fluid/Electrolyte Disorders	32 (20.9%)	0 (0%)	6 (8.6%)	62 (7.3%)	17 (9.2%)	<0.0
	Metastatic Cancer	1 (0.7%)	0 (0%)	2 (2.9%)	14 (1.6%)	2 (1.1%)	0.74
	Other Neurological Disorders	1 (0.7%)	0 (0%)	2 (2.9%)	36 (4.2%)	1 (0.5%)	0.03
	Obesity	3 (2.0%)	0 (0%)	6 (8.6%)	22 (2.6%)	10 (5.4%)	0.0
	Paralysis	2 (1.3%)	0 (0%)	2 (2.9%)	16 (1.9%)	1 (0.5%)	0.6
	Peripheral Vascular Disorders	113 (73.9%)	0 (0%)	12 (17.1%)	355 (41.8%)	112 (60.5%)	<0.0
	Psychoses	2 (1.3%)	0 (0%)	1 (1.4%)	7 (0.8%)	1 (0.5%)	0.93
	Pulmonary Circulation	0 (0%)	0 (0%)	2 (2.9%)	1 (0.1%)	0 (0%)	<0.0
	Disorders						
	Renal Failure	23 (15.0%)	0 (0%)	12 (17.1%)	105 (12.4%)	18 (9.7%)	0.43
	Solid Tumor	2 (1.3%)	0 (0%)	3 (4.3%)	17 (2.0%)	3 (1.6%)	0.66
	Peptic Ulcer	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	
	Valvular Disease	1 (0.7%)	1 (50.0%)	2 (2.9%)	11 (1.3%)	1 (0.5%)	<0.0
	Weight Loss	6 (3.9%)	0 (0%)	0 (0%)	13 (1.5%)	8 (4.3%)	0.0
vasive Diagnos	stic Procedure	4 (2.6%)	0 (0%)	2 (2.9%)	13 (1.5%)	2 (1.1%)	0.7
ırgical Procedu	ıre	147 (96.1%)	1 (50.0%)	47 (67.1%)	742 (87.3%)	173 (93.5%)	<0.0
vasive or Surg	ical Procedure	148 (96.7%)	1 (50.0%)	47 (67.1%)	743 (87.4%)	173 (93.5%)	<0.0
eceased		7 (4.6%)	0 (0%)	2 (2.9%)	13 (1.5%)	3 (1.6%)	0.16
		Mean (SD)	р				
ge, Years		71.44 (5.53)	67.00 (1.41)	76.97 (8.23)	76.64 (7.38)	73.22 (5.84)	<0.0
lodified Frailty	Index Score	1.67 (0.98)	1.00 (1.41)	1.46 (0.93)	1.53 (0.94)	1.48 (0.90)	0.28
	Diagnostic Procedure, Days	0 (0)	-(-)	1.00 (-)	2.40 (3.63)	0 (-)	0.67
ime to Invasive				` '			
	Procedure Days	0 // / 1 631	-(-1				
ime to Surgical	Procedure, Days	0.27 (1.63)	-(-) 2 00 (1 41)	0.53 (1.18)	0.54 (2.22)	0.28 (0.94)	
	of Stay, Days	6.59 (6.19) 71,244	2.00 (1.41) 17,970	4.31 (3.67) 34,388	4.81 (6.11) 47,406	4.23 (5.76) 48,777	0.32 0.0 0 <0.0



Table 7. Backward logistic regression analysis to evaluate the associations between mortality and different factors in emergency-admitted patients with the primary diagnosis of arterial embolism and thrombosis who had an operation.

Mortality was the dependent variable. NIS 2004-2014.

Patients' Characteristics	Adults with Opera	tion	Elderly with Operation		
	OR (95% CI)	P	OR (95% CI)	P	
Modified Frailty Index Score	1.714 (0.836, 3.514)	0.14	1.810 (1.151, 2.846)	0.01	
Time to Operation, Days	1.043 (0.691, 1.575)	0.84	Removed		
Sex, Female			2.850 (1.094,7.423)	0.03	
Age, Years					
Race	Removed Via				
Income Quartile	Backward		Removed Via		
Embolism/Thrombosis	Баскwaru Elimination		Backward		
Location	Elimination		Elimination		
Health Care Insurance					

Discussion

Our findings have demonstrated that in operated patients with arterial thromboembolism, admitted emergently to the hospital, delayed operation and frailty index for adults, and female sex and frailty index for elderly were the main risk factors of mortality.

Frailty index and Mortality

In support of our results, previous studies have shown that frailty index is an important predictive variable in emergency general surgery patients and therefore can be used to assess risk of morbidity and mortality in these cases and serve as an invaluable preoperative risk assessment tool for the acute care surgeon.

Delayed Operation and Mortality

Additionally, in support of our conclusions, delayed operating room access for emergency surgery have been shown to be associated with increased risk of in hospital mortality and longer length of stay. In several NIS studies, delayed operation emerged as a risk factor for mortality in patients with chronic duodenal ulcer, hemorrhoids or ventral hernia who emergently admitted and underwent an operation.

Gender and Mortality

Male patients manifested a lower mortality rate compared in comparison with female patients. This findings are consistent with regional studies that have showed a significantly higher mortality for women undergoing surgical revascularization for peripheral arterial disease. Additional suggested explanations for sex differences in outcome have included the delayed recognition of vascular disease in women as a result of the presumed atheroprotective effects of reproductive hormones and the prescription of fewer antiplatelet and lipid-lowering agents to treat atherosclerotic disease in women In terms of anatomic elements, females have been shown to have smaller native and conduit ves-

sel sizes, both of which have been correlated with poor surgical outcomes. Furthermore, a higher likelihood of periprocedural bleeding and infectious complications leading to higher morbidity and mortality has been demonstrated among female patients.

Age and Mortality

Previous studies have shown that the risk of ATE was increased in patients with higher age, male sex, and hypertension. There is an exponential increase in the risk of arterial thrombotic events with age, and the increase in life expectancy in the second half of the 20th century is a major contributor to increase in ATE events. Plasma concentrations of some coagulation factors (factors V, VII, VIII, and IX, fibringen) increase progressively with age and may play a causative role in the high rate of cardiovascular events observed in elderly people. During aging, an enhanced activity of coagulation enzymes is expressed an impairment of fibrinolytic activity, and an increase in platelet reactivity. Advanced age is characterised by stiffness and dilation of the arteries, due to degeneration of elastic fibres and an increase in collagen and calcium content, and by a decrease in prostacyclin and nitric oxide with a related reduction in endothelium-dependent dilation There is also increased binding of platelet-derived growth factor to arteries, caused by changes in the glycosaminoglycan content of the vessel wall, which enhances the progression of atherosclerosis and indirectly contributes to atherothrombosis. The higher mortality in older age can be explained by a higher postoperative complication risk in older adults as a result of higher rate of comorbidities. Comorbid conditions, as expected, found to have a substantial adverse effect on postoperative outcomes. Hypertension, deficiency anemias, fluid/electrolyte disorders, uncomplicated diabetes, peripheral vascular disease and chronic pulmonary disease have shown to be associated with increased mortality rates.

Comorbidities Deficiencies Anemias, Surgery and Mortality



In multivariate analysis, use of RBC to deficiency anemia cancer patients, was significantly associated with VTE, ATE, and in-hospital mortality after adjusting for other covariates. Anemia is a marker of increased risk during interventional procedure and poor midterm survival after percutaneous coronary intervention. Preoperative anemia was recognized risk factors for operative mortality resulting in increased length of hospital stay, post-operative complications and death. Anemia has been associated with myocardial ischemia and cardiac morbidity, increased mortality in the presence of significant medical or surgical conditions such as MI, heart failure, hematologic malignancy, renal failure vascular surgery, and radical prostatectomy.

Hypertension, Surgery and Mortality

Hypertension is a major risk factor for causing coronary events, stroke, heart failure, peripheral arterial disease, dissecting aneurysm, chronic kidney disease, and mortality Hypertension in the perioperative and postoperative period increases cardiovascular events, cerebrovascular events, bleeding, mortality and increase in HLOS.

Fluid/electrolyte disorders Surgery and Mortality

The increased morality seen in patients with fluid/electrolyte disorders is consistent with previous studies which have highlighted the significant prevalence of hyponatremia and hypernatremia in surgical patients. Both were significantly and independently associated with postoperative thromboembolism, mortality, morbidity, major bleeding and return to operation room. The effect of hyponatremia on thromboembolic outcome was evident across all age groups, both sexes, patients with or without steroid treatment. The preoperative hypernatremia is associated with increased perioperative 30-day morbidity and mortality.

Diabetes, Surgery and Mortality

Patients with diabetes are at increased risk of morbidity and mortality from CVD. Diabetes is the strongest risk factors of occlusive arterial disease. Both extensive vascular pathology and an enhanced thrombotic environment contribute to premature vascular occlusive events and poor clinical outcome in patients with diabetes. Endothelial cell dysfunction plays a role in all stages of the atherosclerotic process from initiation of atherosclerosis to precipitation of thrombosis Therefore, it has been associated with increase rates of surgical complications and death.

As with any retrospective cohort analysis, there is a level if inherent limitation to the data, hence, it is important to interpret that data with that in mind. Due to the fact that it is a retrospective study using an administrative dataset, there are variables that cannot be obtained, which would help greatly to further contextualize the results. Given that the principal goal of the study was to identify factors that influence postoperative in-hospital mortality in emergency surgery of arterial emboli and thrombus, it would be beneficial to add an additional element of analysis of the causes

of death among patients to satisfy the association notes by cause. Furthermore, measuring mortality attributable to arterial emboli and thrombus is challenging for because of the multifactorial nature of death and the low rates of autopsy in most states. Without a standard method to measure arterial emboli and thrombus -associated mortality, it is challenging to point out reliable representative and comparable estimates across demographic and socioeconomic groups. Another such contextualizing aspect that is missing, given the analysis of patient disposition, is an assessment of functional ability prior to emergency surgery. By identifying the level of care required by the patient, such as home health or skilled nursing facility, there would be a more nuanced understanding of whether or not the disposition is a return to the status quo or an escalation in care status needed by the patient. Additionally, as comorbidities were among the most influential factors that increased mortality in both associations, it would be beneficial to comprehend on how multiple comorbidities potentially interact to impact postoperative recovery of revascularization, due to the synergistic impact on physical stress.

Strengths of the Study

The Healthcare Cost and Utilization Project (HCUP) was established to provide multistate, administrative, population-based data on patients in a uniform format. The data are designed for health services research to enhance health care provision. The National Inpatient Sample (NIS), a large administrative database produced by the Agency for Healthcare Research and Quality (AHRQ), has been progressively used publicly as a countrywide data source, holding much potential and support for the assessment of patterns of care and outcomes for research. It allows novel approaches to investigate disease conditions, optimal care, and patient outcomes. The analysis of the epidemiology of a large sample size of patients with arterial thromboembolism can provide additional insights. Previous studies assessing the prevalence of arterial thromboembolism were confined to small populations from single hospitals or geographic regions. The epidemiology and the demographics of arterial thromboembolism in the total population and its impact on hospitalization and complications, and morbidity and mortality have not been examined. Our study fills part of the gap in our expands the evidence base and helps further understanding arterial thromboembolism in adults and elderly, separately.

Limitations of the Study

Several limitations have to be mentioned in this retrospective analysis. In future studies, the quality of the reported data would benefit from the severity of arterial thromboembolism associated complications. Additionally, the retrospective design, had limitations in recognizing several confounding factors such as the choice of operative approach, the surgeon's level of training, severity of comorbidities, cause of death, and any further modifiable factors that impact postoperative outcomes.

REFERENCES

- 1. Lyaker MR, Tulman DB, Dimitrova GT, Pin RH, Papadimos TJ. Arterial embolism. *Int J Crit Illn Inj Sci.* 2013;3(1):77-87. doi:10.4103/2229-5151.109429
- 2. Control C for D, Prevention (CDC. Venous thromboembolism in adult hospitalizations-United States, 2007-2009. *MMWR Morbidity and mortality weekly report*. 2012;61(22):401-404.
- 3. Wendelboe Aaron M., Raskob Gary E. Global Burden of Thrombosis. *Circulation Research*. 2016;118(9):1340-1347. doi:10.1161/CIRCRESAHA.115.306841
- 4. Raskob G.E., Angchaisuksiri P., Blanco A.N., et al. Thrombosis. *Arteriosclerosis, Thrombosis, and Vascular Biology*. 2014;34(11):2363-2371. doi:10.1161/ATVBAHA.114.304488
- 5. Previtali E, Bucciarelli P, Passamonti SM, Martinelli I. Risk factors for venous and arterial thrombosis. *Blood Transfus*. 2011;9(2):120-138. doi:10.2450/2010.0066-10
- 6. Ueberrueck T, Marusch F, Schmidt H, Gastinger I. Risk factors and management of arterial emboli of the upper and lower extremities. *J Cardiovasc Surg (Torino)*. 2007;48(2):181-186.
- 7. Barnes GD, Kabrhel C, Courtney DM, et al. Diversity in the Pulmonary Embolism Response Team Model: An Organizational Survey of the National PERT Consortium Members. *CHEST*. 2016;150(6):1414-1417. doi:10.1016/j.chest.2016.09.034
- 8. Kucher Nils, Boekstegers Peter, Müller Oliver J., et al. Randomized, Controlled Trial of Ultrasound-Assisted Catheter-Directed Thrombolysis for Acute Intermediate-Risk Pulmonary Embolism. *Circulation*. 2014;129(4):479-486. doi:10.1161/CIRCULATIONAHA.113.005544
- 9. Tu Thomas, Toma Catalin, Tapson Victor F., et al. A Prospective, Single-Arm, Multicenter Trial of Catheter-Directed Mechanical Thrombectomy for Intermediate-Risk Acute Pulmonary Embolism. *JACC: Cardiovascular Interventions*. 2019;12(9):859-869. doi:10.1016/j.jcin.2018.12.022
- 10. Ghaye B, Ghuysen A, Willems V, et al. Severe Pulmonary Embolism:Pulmonary Artery Clot Load Scores and Cardiovascular Parameters as Predictors of Mortality. *Radiology*. 2006;239(3):884-891. doi:10.1148/radiol.2392050075
- 11. Konstantinides Stavros, Geibel Annette, Kasper Wolfgang, Olschewski Manfred, Blümel Liane, Just Hanjörg. Patent Foramen Ovale Is an Important Predictor of Adverse Outcome in Patients With Major Pulmonary Embolism. *Circulation*. 1998;97(19):1946-1951. doi:10.1161/01.CIR.97.19.1946
- 12. Kucher N, Rossi E, De Rosa M, Goldhaber SZ. Prognostic Role of Echocardiography Among Patients With Acute Pulmonary Embolism and a Systolic Arterial Pressure of 90 mm Hg or Higher. *Archives of Internal Medicine*. 2005;165(15):1777-1781. doi:10.1001/archinte.165.15.1777
- 13. Connett MC, Murray DH, Wenneker WW. Peripheral arterial emboli. *The American Journal of Surgery*. 1984;148(1):14-19. doi:10.1016/0002-9610(84)90283-6
- 14. Farhat JS, Velanovich V, Falvo AJ, et al. Are the frail destined to fail? Frailty index as predictor of surgical morbidity and mortality in the elderly. *Journal of Trauma and Acute Care Surgery*. 2012;72(6):1526-1531. doi:10.1097/TA.0b013e3182542fab
- 15. Shinall MC Jr, Arya S, Youk A, et al. Association of Preoperative Patient Frailty and Operative Stress With Postoperative Mortality. *JAMA Surgery*.

- 2020;155(1):e194620. doi:10.1001/jamasurg.2019.4620
- 16. McIsaac DI, Abdulla K, Yang H, et al. Association of delay of urgent or emergency surgery with mortality and use of health care resources: a propensity score-matched observational cohort study. *CMAJ*. 2017;189(27):E905-E912. doi:10.1503/cmaj.160576
- 17. Lin N, Smiley A, Goud M, Lin C, Latifi R. Risk Factors of Mortality in Patients Hospitalized with Chronic Duodenal Ulcers. *Am Surg 2022*.
- 18. Levy Lior, Smiley Abbas, Latifi Rifat. Independent Predictors of In-Hospital Mortality in Elderly and Non-Elderly Adult Patients Undergoing Emergency Admission for Hemorrhoids in the USA: A 10-Year National Dataset. *Am Surg 2022*.
- 19. Smiley A, Levy L, Latifi R. Risk Factors for Mortality in Patients with Ventral Hernia Admitted Emergently: An Analysis of 48,539 Adult Patients. *Surg Technol Int*. 2021;39:sti39/1497.
- 20. Latifi R, Levy L, Reddy M, Okumura K, Smiley A. Delayed Operation as a Major Risk Factor for Mortality Among Elderly Patients with Ventral Hernia Admitted Emergently: An Analysis of 33,700 Elderly Patients. *Surg Technol Int.* 2021;39:sti39/1520.
- 21. Vouyouka AG, Egorova NN, Salloum A, et al. Lessons learned from the analysis of gender effect on risk factors and procedural outcomes of lower extremity arterial disease. *Journal of Vascular Surgery*. 2010;52(5):1196-1202. doi:10.1016/j.jvs.2010.05.106
- 22. Egorova N, Vouyouka AG, Quin J, et al. Analysis of gender-related differences in lower extremity peripheral arterial disease. *Journal of Vascular Surgery*. 2010;51(2):372-378.e1. doi:10.1016/j.jvs.2009.09.006
- 23. Enriquez JR, Pratap P, Zbilut JP, Calvin JE, Volgman AS. Women tolerate drug therapy for coronary artery disease as well as men do, but are treated less frequently with aspirin, -blockers, or statins. *Gender Medicine*. 2008;5(1):53-61. doi:10.1016/S1550-8579(08)80008-3
- 24. AhChong AK, Chiu KM, Wong M, Yip AWC. The Influence of Gender Difference on the Outcomes of Infrainguinal Bypass for Critical Limb Ischaemia in Chinese Patients. *European Journal of Vascular and Endovascular Surgery*. 2002;23(2):134-139. doi:10.1053/ejvs.2001.1564
- 25. Hultgren R, Olofsson P, Wahlberg E. Gender Differences in Patients Treated for Critical Limb Ischemia. *European Journal of Vascular and Endovascular Surgery*. 2005;29(3):295-300. doi:10.1016/j.ejvs.2004.12.010
- 26. Grilz E, Königsbrügge O, Posch F, et al. Frequency, risk factors, and impact on mortality of arterial thromboembolism in patients with cancer. *Haematologica*. 2018;103(9):1549-1556. doi:10.3324/haematol.2018.192419
- 27. Gordon T, Kannel WB. Predisposition to atherosclerosis in the head, heart, and legs. The Framingham study. *JAMA*. 1972;221(7):661-666.
- 28. Nieto FJ. Cardiovascular disease and risk factor epidemiology: a look back at the epidemic of the 20th century. *Am J Public Health*. 1999;89(3):292-294. doi:10.2105/ajph.89.3.292
- 29. Abbate R, Prisco D, Rostagno C, Boddi M, Gensini GF. Age-related changes in the hemostatic system. *Int J Clin Lab Res.* 1993;23(1):1-3. doi:10.1007/BF02592271
- 30. Franchini M. Hemostasis and aging. *Crit Rev Oncol Hematol*. 2006;60(2):144-151. doi:10.1016/j.critrevonc.2006.06.004
- 31. Tracy RP. Hemostatic and inflammatory markers as risk factors for coronary disease in the elderly. *Am J Geriatr Cardiol*. 2002;11(2):93-100, 107.



- doi:10.1111/j.1076-7460.2002.00997.
- 32. Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest. 1987;80(6):1527-1534. doi:10.1172/JCI113238
- 33. Mari D, Mannucci PM, Coppola R, Bottasso B, Bauer KA, Rosenberg RD. Hypercoagulability in centenarians: the paradox of successful aging. Blood. 1995;85(11):3144-3149.
- 34. Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost. 2002;28(6):555-568. doi:10.1055/s-2002-36700
- 35. Gleerup G, Winther K. The effect of ageing on platelet function and fibrinolytic activity. *Angiology*. 1995;46(8):715-718. doi:10.1177/000331979504600810
- 36. Taddei S, Virdis A, Ghiadoni L, et al. Age-related reduction of NO availability and oxidative stress in humans. Hypertension. 2001;38(2):274-279. doi:10.1161/01.hyp.38.2.274
- 37. Feyzi E, Saldeen T, Larsson E, Lindahl U, Salmivirta M. Age-dependent modulation of heparan sulfate structure and function. J Biol Chem. 1998;273(22):13395-13398. doi:10.1074/jbc.273.22.13395
- 38. Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH. Blood Transfusions, Thrombosis, and Mortality in Hospitalized Patients With Cancer. Archives of Internal Medicine. 2008;168(21):2377-2381. doi:10.1001/archinte.168.21.2377
- 39. Lee Paul C, Kini Annapoorna S, Chowdhury A, Edward F, Sharma Samin K. Anemia Is an Independent Predictor of Mortality After Percutaneous Coronary Intervention. Journal of the American College of Cardiology. 2004;44(3):541-546. doi:10.1016/j.jacc.2004.04.047
- 40. Muñoz M, Gómez-Ramírez S, Campos A, Ruiz J, Liumbruno GM. Pre-operative anaemia: prevalence, consequences and approaches to management. Blood Transfus. 2015;13(3):370-379. doi:10.2450/2015.0014-15
- 41. Baron DM, Hochrieser H, Posch M, et al. Preoperative anaemia is associated with poor clinical outcome in non-cardiac surgery patients. Br J Anaesth. 2014;113(3):416-423. doi:10.1093/bja/aeu098
- 42. Lunn JN, Elwood PC. Anaemia and surgery. *Br Med J.* 1970;3(5714):71-73. doi:10.1136/bmj.3.5714.71
- 43. Androne Ana-Silvia, Katz Stuart D., Lund Lars, et al. Hemodilution Is Common in Patients With Advanced Heart Failure. Circulation. 2003;107(2):226-229. doi:10.1161/01.CIR.0000052623.16194.80
- 44. Ezekowitz Justin A., McAlister Finlay A., Armstrong Paul W. Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes. Circulation. 2003;107(2):223-225. doi:10.1161/01.CIR.0000052622.51963.FC
- 45. Hannisdal E, Kildahl Andersen O, Grøttum KA, Lamvik J. Prognostic factors in multiple myeloma in a population-based trial. European Journal of Haematology. 1990;45(4):198-202. doi:https://doi.org/10.1111/j.1600-0609.1990.tb00457.
- 46. Jurkovitz CT, Abramson JL, Vaccarino LV, Weintraub WS, McClellan WM. Association of High Serum Creatinine and Anemia Increases the Risk of Coronary Events: Results from the Prospective Community-Based Atherosclerosis Risk in Communities (ARIC) Study. JASN. 2003;14(11):2919-2925. doi:10.1097/01.ASN.0000092138.65211.71
- 47. Foley RN, Parfrey PS. Cardiac Disease in Chronic Uremia: Clinical Outcome

- and Risk Factors. Advances in Renal Replacement Therapy. 1997;4(3):234-248. doi:10.1016/S1073-4449(97)70032-3
- 48. Ah N, La F, Sh R. Relationship between postoperative anemia and cardiac morbidity in high-risk vascular patients in the intensive care unit. Crit Care Med. 1993;21(6):860-866. doi:10.1097/00003246-199306000-00013
- 49. Hogue CW Jr, Goodnough LT, Monk TG. Perioperative myocardial ischemic episodes are related to hematocrit level in patients undergoing radical prostatectomy. Transfusion. 1998;38(10):924-931. doi:10.1046/j.1537-2995.1998.381098440856.x
- 50. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289(19):2560-2572. doi:10.1001/jama.289.19.2560
- 51. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013;34(28):2159-2219. doi:10.1093/eurheartj/eht151
- 52. Fleisher LA. Preoperative evaluation of the patient with hypertension. JAMA. 2002;287(16):2043-2046. doi:10.1001/jama.287.16.2043
- 53. Howell SJ, Sear JW, Foëx P. Hypertension, hypertensive heart disease and perioperative cardiac risk. Br J Anaesth. 2004;92(4):570-583. doi:10.1093/bja/aeh091
- 54. Wald R, Jaber BL, Price LL, Upadhyay A, Madias NE. Impact of Hospital-Associated Hyponatremia on Selected Outcomes. Archives of Internal Medicine. 2010;170(3):294-302. doi:10.1001/archinternmed.2009.513
- 55. Sherlock M, O'Sullivan E, Agha A, et al. The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. Clinical Endocrinology. 2006;64(3):250-254. doi:https://doi.org/10.1111/j.1365-2265.2006.02432.x
- 56. Temraz S, Tamim H, Mailhac A, Taher A. Could sodium imbalances predispose to postoperative venous thromboembolism? An analysis of the NSQIP database. Thrombosis Journal. 2018;16(1):11. doi:10.1186/s12959-018-0165-5
- 57. Lien YHH. Dysnatremia: a clear and present risk for surgery. *Am J Med*. 2013;126(10):849-850. doi:10.1016/j.amjmed.2013.04.023
- 58. Leung AA, McAlister FA, Finlayson SRG, Bates DW. Preoperative Hypernatremia Predicts Increased Perioperative Morbidity and Mortality. The American Journal of Medicine. 2013;126(10):877-886. doi:10.1016/j.amjmed.2013.02.039
- 59. Hess K, Grant P. Inflammation and thrombosis in diabetes. *Thromb* Haemost. 2011;105(\$ 06):S43-S54. doi:10.1160/THS10-11-0739
- 60. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation. 2004; 109(23 Suppl 1): III27-32. doi:10.1161/01.CIR.0000131515.03336.f8
- 61. Gimbrone MA, García-Cardeña G. Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. *Circ Res.* 2016;118(4):620-636. doi:10.1161/CIRCRESAHA.115.306301
- 62. Beckman JA, Creager MA, Libby P. Diabetes and AtherosclerosisEpidemiology, Pathophysiology, and Management. JAMA. 2002;287(19):2570-2581. doi:10.1001/jama.287.19.2570